Neuland to open $20m* dedicated Process Development facility with integrated kilo labs in Hyderabad

New facility will open by October 2026 and house 500 process development specialists

Hyderabad, India, June 15, 2026: Neuland Laboratories [NLL] (NSE: NEULANDLAB; BSE:524558) – a global contract development and manufacturing organization (CDMO) specialising in complex APIs –will open a dedicated process development laboratory and integrated kilo lab at its Genome Valley campus in Hyderabad. The new 135,000 sq. ft. facility will see $20m invested in a specialist fit-out and be operationalised in phases, with full completion expected by October 2026.

Significantly, it has been designed as a purpose-built integrated scale-up laboratory dedicated exclusively to process development. Once completed, the site will take Neuland's process development team to more than 500 scientists, making it one of the largest scale-up workforce in India.

Unlike many CDMOs, where process development laboratories may also support discovery or other mixed-use workstreams, the new facility has been designed exclusively for process development. It will also integrate non-GMP kilo labs, allowing scientists to evaluate process performance at larger scales without transferring work to separate sites or competing for access to GMP capacity. This enables teams to continue process optimisation while generating real-time scale-up data in parallel.

The centre will incorporate AI-driven route scouting, parallel synthesis, and Electronic Laboratory Notebooks (ELNs), enabling faster decision-making, reduced cycle times, and seamless data continuity. A centralised analytical wing will house a comprehensive suite of characterisation technologies, with the facility also including specialised zones for process engineering, polymorph studies, process safety, and advanced flow chemistry, alongside five peptide labs and three purification labs.

"The new facility is particularly notable for a few reasons. Firstly, we are using a pre-existing building, so the full $20m investment is being directed towards fitting out the facility rather than constructing the shell. Alongside this, the facility has also been set up with equipment that simulates large-scale reactions at small scale. The end goal is to give clients parallel development and earlier manufacturability insight from the outset," commented Saharsh Davuluri, Vice Chairman and MD at Neuland Labs.

Automated workflows will streamline routine tasks, enhance reproducibility, and minimise manual intervention, while predictive modelling and data-driven insights guide route selection. By simulating scale-up processes earlier, Neuland can identify failing synthetic routes sooner and remove redundant tests and experiments.

The Kilo Lab will be equipped with 20–250L all-glass reactors, cryogenic capability, and multiple filtration systems. By bridging bench chemistry and plant operations, the Kilo Lab ensures processes are engineered with manufacturability in mind from the outset.

Saharsh added: *"When you look at our existing expertise in novel commercial-scale API production and combine it with our new dedicated process development labs, specifically designed to support scale-up from Phases I–IV, we have an incredibly attractive proposition for both pharma and biotech partners. In practical terms, it means we are able to run the scale*

*189 Crore INR

and chemistry needed today, while also anticipating scale-up challenges and beginning to prepare for commercial production as soon as a project comes to us. There are few CDMOs able to operate this way, and it is one of the benefits of working with a true API specialist like Neuland."

-ENDS-

Notes to editors

About Neuland Labs

Neuland Laboratories Limited [Neuland] is a specialist API CDMO partner for big pharma and biotech – delivering world-class process development and commercial supply services for the most complex molecules and New Chemical Entities. Serving clients in over 80 countries, Neuland operates three US FDA and EU GMP-compliant facilities in India, with a combined reactor capacity of approximately 1218kL. The CDMO invested in a new commercial scale peptide facility in 2026, and is opening a large, dedicated R&D process development centre in Hyderabad.

Neuland is listed on the NSE (NEULANDLAB) and BSE (524558) in India. The company has filed over 1000 DMFs globally – as it also supports generic drug substance providers – and offers more than 100 APIs across multiple therapeutic areas

Disclaimer: This press release may contain certain forward-looking statements, including statements regarding business strategy, future operations, growth plans, expansion initiatives, and leadership priorities. These statements are based on management's current expectations and assumptions and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.

*189 Crore INR